FEATURED NEWS
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations. Read more
LATEST NEWS
Dr. David Barbie and his team will receive a 4-year, $2.5 million grant to support their research on immune-based approaches to target drug-resistant cancer cells. Read more
European Medicines Agency recommends repotrectinib for ROS1-positive NSCLC; FDA approves therapies for NSCLC, LS-SCLC as well as a new diagnostic tool for identifying MET exon 14 s... Read more
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more